Skip to main content
NCBI home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1964 Nov 7;91(19):991–996.

The Relationship of Dosage Schedule to the Blood Level of Quinidine, Using All Available Quinidine Preparations

W M Goldberg, Siba G Chakrabarti
PMCID: PMC1928075  PMID: 14222674

Abstract

Blood quinidine levels obtained by single and multiple dosage schedules of all available quinidine preparations were ascertained. A maintenance blood level of 4 to 7 mg./l. of quinidine was considered a desirable range to prevent recurrence of auricular fibrillation in patients previously converted to sinus rhythm. Quinidine sulfate, quinidine gluconate, dihydroquinidine gluconate and quinidine polygalacturonate were given in dosage schedules of one tablet (equivalent to 200 mg. quinidine) every eight hours for four days, then two tablets every eight hours for three days. Blood quinidine levels were determined the same time each day. Schedules of two tablets of quinidine sulfate or quinidine gluconate every eight hours resulted in blood levels between 4 and 7 mg./l. Similar dosage schedules of the other preparations did not produce levels of this order, nor did quinidine polygalacturonate administered in a 12-hourly schedule. Serious respiratory arrest occurred in one case following quinidine sulfate. No other toxic reactions were noted in this study.

Full text

PDF
991

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BALL R. E., SOKOLOW M. Factors influencing conversion of chronic atrial fibrillation with special reference to serum quinidine concentration. Circulation. 1956 Oct;14(4 Pt 1):568–583. doi: 10.1161/01.cir.14.4.568. [DOI] [PubMed] [Google Scholar]
  2. BELLET S., FINKELSTEIN D., GILMORE H. Study of a long-acting quinidine preparation: experience in normal subjects and in patients with myocardial abnormality. AMA Arch Intern Med. 1957 Nov;100(5):750–758. doi: 10.1001/archinte.1957.00260110066010. [DOI] [PubMed] [Google Scholar]
  3. DITLEFSEN E. M. L. Concentrations of quinidine in blood following delayed-absorption tablets. Acta Med Scand. 1954;149(1):49–53. doi: 10.1111/j.0954-6820.1954.tb11412.x. [DOI] [PubMed] [Google Scholar]
  4. EDGAR A. L., SOKOLOW M. Experiences with the photofluorometric determination of quinidine in blood. J Lab Clin Med. 1950 Sep;36(3):478–484. [PubMed] [Google Scholar]
  5. HALPERN A., SHAFTEL N., MONTE BOVI A. J. The synthesis and study of quinidine polygalacturonate. Am J Pharm Sci Support Public Health. 1958 Jun;130(6):190–201. [PubMed] [Google Scholar]
  6. LOVE W. D. The basis of quinidine therapy. Am J Med Sci. 1955 Jan;229(1):89–102. doi: 10.1097/00000441-195501000-00015. [DOI] [PubMed] [Google Scholar]
  7. LOWN B., AMARASINGHAM R., NEUMAN J. New method for terminating cardiac arrhythmias. Use of synchronized capacitor discharge. JAMA. 1962 Nov 3;182:548–555. [PubMed] [Google Scholar]
  8. POTE H. H. Evaluation of a new quinidine compound: a comparative study. Angiology. 1961 Jul;12:320–323. doi: 10.1177/000331976101200710. [DOI] [PubMed] [Google Scholar]
  9. SAMPSON J. J., FOREMAN H., SOLOMON B. C. Studies of plasma quinidine content. III. The value of delayed absorptive coated tablets in oral quinidine therapy. Circulation. 1952 Apr;5(4):534–538. doi: 10.1161/01.cir.5.4.534. [DOI] [PubMed] [Google Scholar]
  10. SCHWARTZ G. A clinical evaluation of quinidine polygalacturonate. Angiology. 1959 Apr;10(2):115–119. doi: 10.1177/000331975901000206. [DOI] [PubMed] [Google Scholar]
  11. SHAFTEL N., HALPERN A. The quinidine problem. Angiology. 1958 Feb;9(1):34–46. doi: 10.1177/000331975800900108. [DOI] [PubMed] [Google Scholar]
  12. TRICOT R., NOGRETTE P. The management of cardiac arrhythmias with quinidine polygalacturonate. Am J Med Sci. 1962 Feb;243:215–221. [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES